Amicus Therapeutics Inc. Stock
Amicus Therapeutics Inc. Stock
Amicus Therapeutics Inc. gained 0.810% compared to yesterday.
Our community is currently high on Amicus Therapeutics Inc. with 4 Buy predictions and 0 Sell predictions.
With a target price of 14 € there is a slightly positive potential of 12.9% for Amicus Therapeutics Inc. compared to the current price of 12.4 €.
So far the community has only identified positive things for Amicus Therapeutics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Amicus Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amicus Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc. | 0.810% | 0.000% | 3.333% | 54.037% | 3.333% | 16.629% | 37.778% |
| Repligen Corp. | 0.850% | -3.412% | -10.586% | -25.266% | -29.059% | -36.639% | -38.643% |
| Opko Health Inc. | 4.260% | 4.259% | -0.419% | -34.915% | -8.384% | -10.438% | -72.174% |
| Viatris Inc. | -1.380% | -2.419% | -10.425% | 41.667% | 12.957% | 29.969% | -1.653% |
Comments
Amicus Therapeutics (NASDAQ:FOLD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $17.00 price target on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for FOLD provided by MarketBeat